The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- Moderna Vaccines to Arrive in Japan Next Week
April 14, 2021
- Japan to Prioritize Screening for N501Y Variant; E484K “Does Not Render Vaccines Ineffective”: Minister
April 14, 2021
- LDP Pharma Study Group to Discuss R&D Support, Eyes Proposal
April 13, 2021
- Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
- Japan Starts COVID-19 Vaccinations for 36 Million Elderly
April 13, 2021
- COVID-19 Vaccine Reactions More Common in Women, Younger People: MHLW Study
April 12, 2021
- Vaccine Safety Panels to Evaluate Suspected Anaphylaxis Cases Based on Pfizer’s Reports
April 12, 2021
- Development of Japan-Made Vaccines “Significantly Meaningful”: Minister
April 12, 2021
- MSD’s Recarbrio Up for PAFSC Review on April 21
April 8, 2021
- Label Update Will Suffice to Expand COVID-19 Vaccination Age: MHLW Official
April 7, 2021
- AMED to Set Up Council to Hone Academic Seeds with Industry Input
April 7, 2021
- MHLW Launches New Office to Fuel SaMD Commercialization
April 6, 2021
- MHLW to Consider Ways to Address Listing Delays Linked to Off-Year Re-Pricing: Official
April 6, 2021
- Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
April 6, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- Ex-PMDA Inspector Urges Improvements in Japanese Inspection Systems after GMP Scandals
April 5, 2021
- Japan Mulls Expanding COVID-19 Vaccination Age to 12-15
April 5, 2021
- MHLW Calls for Thiola’s Priority Use for Cystinuria as Shortage Expected
April 2, 2021
- Neurosurgical Expert Eager to Carry Out Bridging Study of Cannabis-Derived Drug in Japan
April 2, 2021
- Japan Publishes Cost-Effectiveness Analysis Reports for Kymriah, Trelegy
April 1, 2021
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…